Corresponding to these potential immunostimulatory effects at the tumor site, we observed strong recruitment of activated and antigen-presenting (MHC-IIHI/CD86+ or MHC-IIHI/CD80+) M1-like macrophages into Renca tumor-draining lymph nodes by CpG-STAT3ASO and the combination treatment resulting in three- to four-fold increase of the activated macrophages compared with PBS- or antibody-treated controls (Figure 6C). This evidence concerns the gene CD86 and neoplasm.